Jianxin Chen

Dr. Jianxin Chen

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
YPYonghai Peng
Yonghai Peng
JWJian Wang
Jian Wang
JWJunhui Wang
Junhui Wang
JCJianxin Chen
Jianxin Chen
Background: Patients with refractory mismatch repair-proficient/microsatellite stable (pMMR/MSS) metastatic colorectal cancer exhibit intrinsic resistance to immune checkpoint inhibitors and conventional salvage therapies, with median overall survival (OS) is typically less than 10 months. This study evaluates the novel BRICS sequential regimen (Bifidobacterium supplementation, Radiotherapy, Immunotherapy, Chemotherapy, Stereotactic approach) in this population.Methods: In this retrospective analysis, 27 refractory pMMR/MSS metastatic CRC patients received BRICS: Stereotactic body radiotherapy to a single lesion, indefinite high-dose probiotics, followed by low-dose chemotherapy plus PD-1 inhibitor. Primary endpoints were objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and OS.Results: Efficacy outcomes: ORR 33.3% (9 partial responses), DCR 88.9%, median PFS 7.20 months (95% CI: 5.23–9.18), and median OS 12.30 months (95% CI: 9.89–14.71). Eastern Cooperative Oncology Group Performance Status (ECOG PS) >2 independently predicted inferior OS (HR = 4.860; p=0.042), while metastatic burden (≥3 organs) predicted shorter PFS (HR = 3.179; p=0.026). Grade 3–4 adverse events occurred in 22.2% of patients (neutropenia: 14.8%; thrombocytopenia: 3.7%; anemia: 3.7%).Conclusions: BRICS demonstrates clinically meaningful efficacy (DCR 88.9%, mOS 12.3 months) and manageable toxicity in refractory pMMR/MSS metastatic CRC. ECOG PS >2 and high metastatic burden identify patients with limited benefit, warranting prospective validation in biomarker-enriched cohorts.

15 October 2025 in Annals of Medicine
Verified
Journal Article
Open access
JWJunhui Wang
Junhui Wang
JWJian Wang
Jian Wang
JCJianxin Chen
Jianxin Chen
Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) have revolutionized the treatment landscape for Non-Small Cell Lung Cancer (NSCLC). However, resistance invariably curtails their long-term efficacy. This comprehensive review delineates the intricate mechanisms underpinning EGFR TKI resistance and the evolving therapeutic counterstrategies. We present a panoramic atlas of resistance mechanisms, encompassing on-target resistance, bypass pathway activation, histologic transformation, and metabolic reprogramming, alongside their clinical classification. The discussion extends to the integrated diagnostic technologies facilitating resistance detection, including multi-dimensional biopsy approaches and multi-omics fusion analysis. We critically evaluate precision therapeutic approaches tailored to specific resistance alterations, such as C797S mutations and mesenchymal-epithelial transition amplification, and explore the burgeoning field of novel agents like fourth-generation TKIs and antibody-drug conjugates (ADCs). Furthermore, innovative combination strategies and the challenges within resistance management systems, including toxicity profiles and unresolved scientific questions, are examined. A profound understanding of EGFR resistance mechanisms and the continuous refinement of therapeutic paradigms are paramount for improving the prognosis of NSCLC patients.

23 February 2024 in Medicine
Verified
Journal Article
Open access
JCJianxin Chen
Jianxin Chen
QZQinhong Zheng
Qinhong Zheng
JWJunhui Wang
Junhui Wang
XZXueli Zhang
Xueli Zhang
YLYingguo Lv
Yingguo Lv
The present study was conducted to characterize the clinicopathologic characteristics, immunohistochemical staining results, and immune checkpoint inhibitors (ICIs) efficacy in patients with SMARCA4-deficient/TP53 mutant lung cancer. Patients diagnosed with advanced or metastatic undifferentiated lung cancer harboring SMARCA4-deficient and TP53 mutations, however, without targetable sensitive mutations were retrieved from the electronic medical record system. Descriptive statistics were used to describe the baseline characteristics and clinical features including age, gender, eastern cooperative oncology group performance status, disease stage, smoking status, chief complaint, site of the primary mass, tumor size, gross type, symptoms, local invasion, and metastatic sizes. Immunological markers and potential drive genes were detected by immunohistochemical staining and next generation sequencing. Efficacy and safety profile of ICIs in included patients was evaluated with progression-free survival and overall survival. Between January 2019 and September 2022, there were 4 patients included within the inclusion criteria in the present study. Biomarkers including CK, CK7, and integrase interactor 1 were detected positive, however, other immunological markers including CK20, CD56, P63, P40, NapsinA, TTF-1, CgA, Syn, BRG1, or PD-L1 were detected negative among them. Results of next generation sequencing panel were failed to discover any targetable sensitive mutations. A total of 4 mutation types of TP53, including p.C141Y, p.S240G, p.E339X (terminator acquired), and p.L130F detected for the patients, respectively. Microsatellite stability status, as well as low tumor mutation burden was identified among all the patients. Median progression-free survival for ICIs as first line treatment and median overall survival were 3.25 months (range from 1.3 to 6.8 months), and 6.0 months (range from 2.7 to 9.6 months), respectively. Our results indicated that advanced lung cancer patients harboring co-occurring SMARCA4-deficient/TP53 mutations might respond to ICIs treatment, though within negative programmed cell death-ligand 1 expression or low tumor mutation burden. However, hyperprogressive disease by ICIs may also happen for such patients. The mutation types of TP53 might play a role during the exposure of ICIs, however, need further identification in basic experiments.

21 July 2016 in Integrative Cancer Therapies
Verified
Journal Article
Open access
PDF file
JCJianxin Chen
Jianxin Chen
XQXu Qingxia
Xu Qingxia
WJWang Junhui
Wang Junhui
ZQZheng Qinhong
Zheng Qinhong
Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies worldwide. Although surgery is known as the most promising radical treatment, a high recurrent or metastatic rate after surgery has limited its clinical efficacy. Sorafenib, a target agent, has seemed to be the only option for metastatic HCC patients to date, but none of clinical trials showed it could prolong the overall survival (OS) of advanced HCC to 1 year. How to prolong the OS and improve cure rate of HCC patients is still beset with difficulties. This report presents a rare case of recurrent HCC patient with complete regression of target lesion with 2 years of Chinese herbal treatment. A 64-year-old Chinese man with hepatitis B virus–associated chronic hepatitis presented HCC has been clinically diagnosed tumor relapse and omentum metastasis with computed tomography and α-fetoprotein blood test 4 months after surgery. It was decided the patient would receive traditional Chinese medicine treatment because of poor prognosis. After approximately 2 years of treatment, recurrent hepatic tumor and omentum metastasis have been found in complete regression. The patient remains alive over 31 months after relapse.

8 February 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JWJunhui Wang
Junhui Wang
JCJianxin Chen
Jianxin Chen
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have been emerged as the standard selection in non-small cell lung cancer (NSCLC) patients with EGFR sensitive mutations. However, primary or acquired resistance to EGFR-TKIs seems inevitable, especially to third-generation TKIs, which has appeared absence of effective solutions so far. Here we reported a NSCLC patient with EGFR sensitive mutation of deletion within EGFR exon 19, who had been resistant to icotinib and AZD9291 successively after a period of 18 months response duration. Next-generation sequencing (NGS) technique using plasma sample suggested an acquired EGFR Leu792H mutation, rather than C797S one. Interestingly, the patient obtained another 8 months of disease-free duration with symptoms greatly relieved after repeating icotinib administration. The overall survival of the patient has been thirty-six months and still in the extension. The presentation of the case may provide some selective therapeutic thoughts for NSCLC patients with acquired EGFR Leu792H mutation suffering resistance to the third-generation TKIs.

11 December 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
JWJian Wang
Jian Wang
BLBingyue Liu
Bingyue Liu
QZQinhong Zheng
Qinhong Zheng
RXRuoshui Xiao
Ruoshui Xiao
JCJianxin Chen
Jianxin Chen
Background: ROS1, a member of the sevenless subfamily of tyrosine kinase insulin receptors, promotes tumor cell survival, proliferation, and metastasis by activating the JAK/STAT, PI3K/AKT, and MAPK/ERK pathways. It only accounts for about 2% of total NSCLC cases. No cases of acquired ROS-1 rearrangement have been reported worldwide.Case presentation: We reported a case of lung adenocarcinoma without driver alteration that developed resistance to pembrolizumab and newly emerged CD74-ROS1 fusion, and achieved a partial response after entrectinib treatment.Conclusions: We hypothesize that the newly emerged ROS1 rearrangement occurs as the subset of cells harboring ROS1 gradually becomes the predominant pathological type of adenocarcinoma following pembrolizumab treatment. We propose that new therapeutic targets may emerge for this patient population following long-term immunotherapy. Thus, we advocate for regular monitoring of tumor genetic status, which could yield unexpected benefits.